Patents by Inventor Marat Alimzhanov

Marat Alimzhanov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TARGETED BINDING AGENTS AGAINST B7-H1
    Publication number: 20230235062
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
    Type: Application
    Filed: November 1, 2022
    Publication date: July 27, 2023
    Inventors: CHRISTOPHE QUEVA, MICHELLE MORROW, SCOTT HAMMOND, MARAT ALIMZHANOV, JOHN BABCOOK, IAN FOLTZ, JASPAL SINGH KANG, LAURA SEKIROV, MELANIE BOYLE, MATTHIEU CHODORGE, ROSS A. STEWART, KATHLEEN ANN MULGREW
  • Targeted binding agents against B7-H1
    Patent number: 11518809
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: December 6, 2022
    Assignee: MEDIMMUNE LIMITED
    Inventors: Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcock, Ian Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Stewart, Kathleen Ann Mulgrew
  • PD-1 AXIS BINDING ANTAGONIST TO TREAT CANCER WITH GENETIC MUTATIONS IN SPECIFIC GENES
    Publication number: 20220241263
    Abstract: The present disclosure describes combination therapies comprising a PD-1 axis binding antagonist, wherein the cancer has been pre-determined to have one or more genetic mutations in one or more genes, to have certain gene expression profiles, and/or to have other biomarkers.
    Type: Application
    Filed: May 29, 2020
    Publication date: August 4, 2022
    Inventors: Marat Alimzhanov, Keith Anthony Ching, Alessandra Di Pietro, Xinmeng Mu, Paul Brian Robbins
  • COMBINATION OF A PD-1 ANTAGONIST, AN ATR INHIBITOR AND A PLATINATING AGENT FOR THE TREATMENT OF CANCER
    Publication number: 20220048997
    Abstract: The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to a therapeutic combination which comprises a PD-1 antagonist, an ATR inhibitor and a platinating agent.
    Type: Application
    Filed: September 26, 2019
    Publication date: February 17, 2022
    Inventors: Marat Alimzhanov, Patricia Soulard, Frank Zenke, Heike Dahmen, Astrid Zimmermann, Andreas Schroeder, Keyvan Tadjalli Mehr, Martin Falk
  • TARGETED BINDING AGENTS AGAINST B7-H1
    Publication number: 20210017282
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
    Type: Application
    Filed: July 23, 2019
    Publication date: January 21, 2021
    Inventors: CHRISTOPHE QUEVA, MICHELLE MORROW, SCOTT HAMMOND, MARAT ALIMZHANOV, JOHN BABCOCK, IAN FOLTZ, JASPAL SINGH KANG, LAURA SEKIROV, MELANIE BOYLE, MATTHIEU CHODORGE, ROSS A. STEWART, KATHLEEN ANN MULGREW
  • Targeted binding agents against B7-H1
    Patent number: 10400039
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: September 3, 2019
    Assignee: MEDIMMUNE LIMITED
    Inventors: Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcock, Ian Nevin Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Stewart, Kathleen Ann Mulgrew
  • ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY
    Publication number: 20170240639
    Abstract: Disclosed herein are ActRII antagonists and methods for increasing immune responses and/or activity in patients in need thereof including, for example, cancer patients. In some embodiments, the disclosure relates to methods for treating cancer and/or tumors in a patient comprising administration of an ActRII antagonists and a PD1-PDL1 antagonist.
    Type: Application
    Filed: February 22, 2017
    Publication date: August 24, 2017
    Inventors: Ravindra Kumar, Marat Alimzhanov, Robert Scott Pearsall
  • TARGETED BINDING AGENTS AGAINST B7-H1
    Publication number: 20170137522
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
    Type: Application
    Filed: October 25, 2016
    Publication date: May 18, 2017
    Applicant: MEDIMMUNE LIMITED
    Inventors: CHRISTOPHE QUEVA, MICHELLE MORROW, SCOTT HAMMOND, MARAT ALIMZHANOV, JOHN BABCOCK, IAN Nevin FOLTZ, JASPAL SINGH KANG, LAURA SEKIROV, MELANIE BOYLE, MATTHIEU CHODORGE, ROSS A. STEWARD, KATHLEEN ANN MULGREW
  • Targeted binding agents against B7-H1
    Patent number: 9493565
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: November 15, 2016
    Assignee: MedImmune Limited
    Inventors: Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcock, Ian Nevin Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Steward, Kathleen Ann Mulgrew
  • TARGETED BINDING AGENTS AGAINST B7-H1
    Publication number: 20140356353
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
    Type: Application
    Filed: May 6, 2014
    Publication date: December 4, 2014
    Inventors: CHRISTOPHE QUEVA, MICHELLE MORROW, SCOTT HAMMOND, MARAT ALIMZHANOV, JOHN BABCOCK, IAN Nevin FOLTZ, JASPAL SINGH KANG, LAURA SEKIROV, MELANIE BOYLE, MATTHIEU CHODORGE, ROSS A. STEWARD, KATHLEEN ANN MULGREW
  • Targeted binding agents against B7-H1
    Patent number: 8779108
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: July 15, 2014
    Assignee: MedImmune, Limited
    Inventors: Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcook, Ian Nevin Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Stewart, Kathleen Ann Mulgrew
  • Targeted Binding Agents Against B7-H1
    Publication number: 20130034559
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed.
    Type: Application
    Filed: November 24, 2010
    Publication date: February 7, 2013
    Applicant: Medlmmune Limited
    Inventors: Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcook, Ian Nevin Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Stewart, Kathleen Ann Mulgrew